Skip to main content

Table 6 Multi-variate analysis of clinical characteristics on progression free and overall survival in patients with metastatic non-small cell lung cancer

From: Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review

Variable

PFS: HR (95% CI)

P = value

OS : (95% CI)

P = value (a)

Age <60 years

1.46 (1.03-2.07)

0.03

1.64 (1.14-2.36)

0.006

No chemotherapy

2.04 (1.38-3.01)

0.0003

2.12 (1.42-3.18)

0.0002

Mets 1-2

0.56 (0.39-0.79)

0.001

0.69 (0.49-0.97)

0.03

ALI <18

1.66 (1.18-2.33)

0.003

1.42 (1.003-2.01)

0.047

  1. a) Cox proportional hazard regression model, Variables adjusted included sex, race, Performance status, histology.
  2. ALI advanced lung cancer inflammation index, Mets metastatic sites. Significant results shown in bold.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us